Do you want to read an article? Please log in or register.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Breast Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Breast Cancer
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
Breast.
Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M
doi: 10.1016/j.breast.2017.12.016.
Breast Cancer
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Lancet Oncol.
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS
doi: 10.1016/S1470-
Breast Cancer
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients
Eur J Cancer.
Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulins I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T
doi: 10.1016/j.ejca.2018.03.013.
Breast Cancer
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Breast Cancer Res.
Edith A. PerezEmail, José Manuel López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia and Michael Andersson
doi: 10.1186/s13058-016-0773-6
Breast Cancer
First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Breast.
Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y
doi: 10.1016/j.breast.2017.06.015.
RECOMMENDED
Breast Cancer
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
doi: 10.1016/S1470-2045(20)30112-1.
Breast Cancer
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Ann Oncol.
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D
doi: 10.1093/
RECOMMENDED
Breast Cancer
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Eur J Cancer.
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN, GEICAM Spanish Breast Cancer Group., GBG (German Breast Group)., Alliance for Clinical Trials in Oncology (Alliance).
doi: 10.1016/j.ejca.2019.06.002.